Currently, many novel therapies are available for physicians treating cancer; some of them are associated with
adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing
the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this
issue. We report a review of old and new commonly used agents with torsadogenic potential.
Keywords: Adverse cardiac events, cancer, QT prolongation, through QT study, torsade de point.
Rights & PermissionsPrintExport